Latest news

EMA grants Orphan Drug Designation to Debiopharm International SA’s FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer

Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with…

GenePOC Launches its new GenePOC™ GBS DS test

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award

Le professeur Peter Vogel nommé titulaire de la nouvelle chaire Debiopharm de philanthropie familiale à l’IMD

Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…

GenePOC Announces an Exclusive Distribution Agreement with Cardinal Health covering the US market